Successful Withdrawal from Dobutamine by Canagliflozin in a Diabetic Patient with Stage D Heart Failure
-
- Nakagaito Masaki
- Second Department of Internal Medicine, University of Toyama
-
- Joho Shuji
- Second Department of Internal Medicine, University of Toyama
-
- Ushijima Ryuichi
- Second Department of Internal Medicine, University of Toyama
-
- Nakamura Makiko
- Second Department of Internal Medicine, University of Toyama
-
- Hirai Tadakazu
- Second Department of Internal Medicine, University of Toyama
-
- Kinugawa Koichiro
- Second Department of Internal Medicine, University of Toyama
Search this article
Description
<p>Patients with stage D heart failure (HF) frequently become dependent on high doses of diuretics and inotropic agents. Recently, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), an oral antidiabetic agent, has been demonstrated to have favorable effects in preventing HF. However, it remains unknown whether SGLT2i is reliable for patients with decompensated HF. We experienced a case of a patient with stage D HF for whom attempting intravenous dobutamine withdrawal was difficult even after the administration of all conventional pharmacological treatment. Administration of canagliflozin produced an additive diuretic action and correction of volume overload in combination with azosemide and tolvaptan, and resulted in successful withdrawal of dobutamine. Thus, SGLT2i might be promising for the treatment of patients with congestive HF who are refractory to conventional diuretic treatment.</p>
Journal
-
- International Heart Journal
-
International Heart Journal 58 (6), 978-981, 2017
International Heart Journal Association
